Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Drugs Laggard
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
(
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.2%. By the end of trading, Questcor Pharmaceuticals fell $0.51 (-1.1%) to $46.96 on light volume. Throughout the day, 913,167 shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 2,024,200 shares. The stock ranged in price between $46.52-$47.83 after having opened the day at $47.66 as compared to the previous trading day's close of $47.47. Other companies within the Drugs industry that declined today were:
Senesco Technologies
(
SNTI
), down 11.6%,
(
), down 10.8%,
(
), down 10.3% and
(
), down 8.1%.
Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $2.9 billion and is part of the health care sector. Shares are up 78.6% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.
TheStreet Ratings rates
Questcor Pharmaceuticals
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
- You can view the full Questcor Pharmaceuticals Ratings Report.
On the positive front,
(
), up 38.5%,
(
), up 32.5%,
(
), up 9.3% and
(
), up 7.9% , were all gainers within the drugs industry with
(
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null